JULY - 202319TECH OUTLOOKinnovations are the FluroTec® barrier film and SmartDose® Drug Delivery PlatformIn the case of FluroTec®, we were approached by a client for a traditional storage solution which could meet container closure integrity during cold storage and sterilization. The solution must not be susceptible to the usual limitations of cryovials such as mechanical strength and flange consistency, while retaining the standard oncological containment requirements such as silicone and molecule sensitivity. A unique challenge arising from the increasingly complex drugs that are being discovered for oncological treatments. Our solution was to use our FluroTec film-coated stoppers in conjunction with Daikyo Crystal Zenith® vial. The combination allows cells to be stored up to six months in cold storage, and yet have >95 percent viability rapid recovery after two hours of thawing. Today, our FluroTec film has the US FDA's approval for use with over 125 drugs, including vaccines. With the Center for Drug Evaluation (CDE) of National Medical Products Administration of China (NMPA) recent publication of technical guidelines for biopharmaceutical research and evaluation highlighting the need for quality risk management within the industry, we are confident that more researchers will find our innovation helpful.In another scenario, we develop a convenient and integrated solution for the administration of biological therapies to enhance patients' well-being, the SmartDose® wearable injector, a platform designed for high-viscosity and silicone-sensitive biologic formulations. It allows users to eliminate the need for a nurse and enhance treatment compliance through its automatic needle protection and portability feature. Through SmartDose drug delivery platform, we broadened our ability to balance the safety and well-being of patients with the technical demands of our pharmaceutical partners, particularly for wearable drug delivery systems.Innovation With Customers Asia Pacific is a diverse and dynamic region. As an industry leader, we strive to deliver the best quality products and offerings while ensuring we meet the varied unique needs and demands of the industry. We do this by encouraging collaborations, fostering the conception of new ideas and promoting the adoption of new technologies.Within the region, we support a wide range of research initiatives with over 15 different academic partners and partnered with biotechnology companies to co-develop new biologics and therapeutics. Our efforts have led to more than 100 scientific publications, presentations and book chapters that furthered the science of injectable medicine containment and delivery. It has also empowered our customers to focus on meeting the industry's evolving needs speedily. While our participation allows us to be privy to exciting new developments, it is a humbling reminder for us to pursue constant innovation. Looking ahead, new developments will continue to emerge from within pharmacology and new drugs will arise. We must adopt new tools such as the Industrial Internet of Things (IIoT) to enhance our abilities in developing new innovations. Since the start of the pandemic, we have invested over US$265 million and hired over 1,000 new members to increase our global manufacturing capacity. We will continue to invest further in our production capabilities to enhance the resilience of our supply chain in order to live up to our commitment of enabling our customers to improve the well-being of patients. Modern biopharmaceutical drug molecules are often complex protein structures or fragile RNAs that need to maintain the molecular structure in order to convey full potencyLi Chen
< Page 9 | Page 11 >